Radical new nerve stimulation treatment that could cure depression WITHOUT medication

Stimulating one of the largest nerves in the body could be the game-changing treatment for depression that researchers have been looking for. 

A recent study found that stimulating the vagus nerve produced long-lasting improvements in people struggling with severe depression, including in people with treatment-resistant depression (TRD) for which traditional pharmacological treatments have failed. 

A two-year study found that 69 percent of patients improved with vagus nerve stimulation via a chest-implanted device similar to a pacemaker that sends low-level electrical pulses along the major nerve. For more than 80 percent of those people, that benefit lasted through the second year. 

The vagus nerves run from the brainstem down through to the abdomen and carry signals between the brain and the body’s major organs, playing a critical role in regulating mood, stress and emotional control — circuits that are disrupted in depression.

Researchers counted a patient as improved if their symptoms decreased by at least 30 percent, or if they saw measurable improvements in their day-to-day functioning. 

About 21 million American adults have depression and roughly 2.8 million to 7 million live with TRD, meaning they have tried at least two antidepressants at the right doses and durations and still have not found relief. 

‘There is a dire need to find effective treatments for these patients, who often have no other options,’ said lead author Dr Charles Conway, a psychiatry professor and director of Washington University’s Treatment Resistant Mood Disorders Center. 

He added: ‘We were shocked that one in five patients was effectively without depressive symptoms at the end of two years.’

The problem with TRD is not only that depression is difficult to treat; it is also that even when a treatment works, it can suddenly stop. Research suggests this affects up to a third of patients on long-term antidepressants.

On average, patients in the study had been stuck in their current depressive episode for 17 years and had already tried — and failed — more than 13 different treatments, including medications, therapy, and even electroshock.

‘We believe the sample in this trial represents the sickest treatment-resistant depressed patient sample ever studied in a clinical trial,’ Conway said.

Most were in their mid-50s, and nearly three-quarters were too sick to work. Their quality of life scores fell below the ‘severe impairment’ line, ranking worse than patients with chronic migraines or rheumatoid arthritis.

Many had been hospitalized for depression and more than 40 percent had attempted suicide at some point in their lives.

A total of 493 patients have had the vagus nerve stimulation (VNS) device surgically implanted under the skin just below the collarbone. From that device, a thin wire runs up to the left vagus nerve in the neck.

The device sends mild, regular electrical pulses through that wire to the vagus nerve, which carries signals between the brain and major organs. These gentle pulses travel up to the brainstem and reach regions involved in mood and emotion.

The implant is designed to stay in place indefinitely, as long as it provides benefit and is tolerated. Battery life for the LivaNova devices used in the RECOVER trial ranges from two to 16 years.

This latest report, published in the International Journal of Neuropsychopharmacology, was a follow-up phase of the larger RECOVER trial testing the durability of benefits. 

The key question in the study was whether the benefits patients gained in the first year would last. 

The main RECOVER trial ran from September 2019 to April 2025, with participants randomized to receive either active VNS or a placebo treatment for 12 months. 

After that first year, 214 patients from the active group continued into a second year of VNS treatment while doctors monitored their progress at regular checkpoints.

To measure whether the treatment was working, the team behind the latest trial used several standard questionnaires.  

They assessed depressive symptoms using three different scales — two completed by clinicians and one by the patients themselves. They also measured daily functioning and quality of life.

The researchers set two thresholds for improvement: a 30 percent reduction in symptoms counted as ‘meaningful benefit,’ while a 50 percent reduction was considered ‘substantial benefit.’

The researchers compared how patients were doing at 12 months versus how they were doing at 18 and 24 months.

They also checked to ensure the improvements were not just due to patients adding new medications or trying other therapies, and found no significant changes in treatment during the second year.

Among the 69 percent of patients who saw meaningful improvement after one year, more than 80 percent of them maintained or built on that progress through the second year across all metrics, including depressive symptoms, quality of life and daily functioning.

And among patients who had not responded at all after 12 months, roughly 30 to 38 percent went on to improve during the second year.

This suggested that for some people, VNS takes some time to work and giving up too early could mean missing out on significant benefits.

By the two-year mark, more than one in five patients had reached remission, meaning their symptoms improved enough that they could function normally again.

The benefits were not driven by patients piling on extra medications or seeking other intensive treatments.

The researchers found no significant changes in medication use during the second year, suggesting that the VNS device itself was having the greatest impact.

The first-line treatment for depression is a combination of medication and therapy. 

The most commonly prescribed antidepressants are SSRIs, such as Zoloft and Prozac, which work by increasing serotonin levels in the brain.

For many, these medications can significantly reduce symptoms and improve daily functioning.

However, these treatments have downsides. Common side effects include nausea, weight gain, sexual dysfunction and emotional blunting, or a feeling of being numb or detached.

For up to a third of patients, standard antidepressants do not work at all. 

When someone has tried two or more medications without success, they are considered to have treatment-resistant depression, and their odds of finding relief with yet another pill drop dramatically.

Conway said: ‘With this kind of chronic, disabling illness, even a partial response to treatment is life-altering, and with vagus nerve stimulation we’re seeing that benefit is lasting.’ 

An important note to consider when reviewing the results – the RECOVER trial is funded by LivaNova PLC, the device’s manufacturer. The company supported the study’s conduct, data analysis and report drafting.  

Several authors also have consulting or funding ties to LivaNova, though the authors say they alone approved the final manuscript.